SCHEMBL3768064

SCHEMBL3768064

Cc1ccc(F)c(-c2cnc(N3CCN(CC(=O)N4CCN(C5CCC5)CC4)CC3)cn2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.42
MAPT P10636 2/20 0.41
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 3/20 0.38
SMO Q99835 2/20 0.38
GRM5 P41594 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ACHE P22303 1/20 0.37
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767713 0.93 HRH3 (0.42) HRH3MAPTCYP11B1CYP11B2LMNA
SCHEMBL3774609 0.91 HRH3 (0.47) HRH3MAPTCYP11B1CYP11B2ALDH1A1
SCHEMBL3769122 0.88 RAB9A (0.44) HRH3ALDH1A1MEN1KMT2APOLB
SCHEMBL3772011 0.87 MAPT (0.44) HRH3MAPTCYP11B1CYP11B2LMNA
SCHEMBL3770158 0.86 HRH3 (0.42) HRH3MAPTCYP11B1CYP11B2ALDH1A1
SCHEMBL3770437 0.86 GRM5 (0.49) HRH3GRM5
SCHEMBL3773713 0.86 HRH3 (0.47) HRH3MAPTCYP11B1CYP11B2LMNA
SCHEMBL3771792 0.86 SMO (0.42) HRH3CYP11B1CYP11B2LMNAALDH1A1
SCHEMBL3763107 0.85 HRH3 (0.43) HRH3MAPTCYP11B1CYP11B2ALDH1A1
SCHEMBL3767947 0.85 HRH3 (0.41) HRH3MAPTALDH1A1NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 HRH3 2/4885MAPT 1475/4885CYP11B1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.